GF-1002 / Genflow Biosci - LARVOL DELTA

Genflow Biosciences PLC Announces Company Update (GlobeNewswire) - "Genflow Biosciences Plc...today announced the receipt of written comments from the Federal Agency for Medicines and Health Products (FAHMP) of Belgium. The Company is pleased with the advice received from the FAHMP to commence clinical trials of its drug, GF-1002, with patients suffering from NASH...(rather than in healthy volunteers). This follows promising results from the Company’s research in in-vitro human cells and in-vivo rodent studies. The Company’s NASH clinical trials are scheduled to begin in approximately 18 months following dialogue and subsequent agreement with the European Medicine Agency....'We are thrilled that the FAHMP has recommended Genflow to commence Phase I/II clinical trials in NASH patients rather than with healthy volunteers. We hope that this will provide a first signal of efficacy in humans more speedily...'"

European regulatory • Metabolic Disorders • Non-alcoholic Steatohepatitis